Too many ETF tickers, too little time. There are officially more ETFs than publicly traded stocks in the U.S., and no normal investor has the time — or the stomach — to sort through thousands of…
GLP-1s are the first line of biotech innovations that are remaking medicine, GPUs are still fueling the AI boom, and the coming SpaceX IPO is about to test investors’ impulse control. That (and more)…
This week on The Big Skinny, Lou Basenese goes straight at three huge market questions: Are semis too crowded? Is Nvidia still a buy? And how big could the SpaceX IPO really be? The setup is simple:…
This week on The Big Skinny, Lou Basenese cuts through the noise after a monster week of earnings from most of the Mag 7 and asks what investors should really take away. The answer: AI demand is real,…
This week on The Big Skinny, Lou Basenese cuts through the noise surrounding the Mag 7 and asks a simple question: is Big Tech really as dominant as the narrative suggests — or is the market already…
This week on The Big Skinny, Lou Basenese asks a timely question: if markets are headed into another storm, what should investors actually own? From bear-market scares and oil-price shocks to…
